You are here

Nuclear Cardiology

 
 - blood clot, platelets, vein

There are a few different quantitative techniques used to measure myocardial blood flow (MBF) and myocardial flow reserve (MFR), both of which have been shown to provide useful information in managing cardiovascular disease. However, MFR measurements appear to be less affected by variables of quantitation when using different arterial input functions and extraction models, according to a comparison study published today in the Journal of Nuclear Medicine.

Nuclear Cardiology
 

Recent Headlines

Lower scan time, dose in SPECT MPI

A new SPECT protocol allows researchers to not only cut scan times down to a quarter of the average time, but it could also be used to lower dose, according to a study published Nov. 20 in the Journal of Nuclear Medicine.

Cardiac PET/CT: Measuring calcification via low-dose CT

Low-dose CT has become a mainstay for PET attenuation correction, but why not take it a step further by quantifying coronary artery calcium without adding any extra dose, according to an Ottawa Heart Institute study published ahead of print Nov. 20 in the Journal of Nuclear Cardiology.

FDG PET reigns for diagnosing infected prosthetic heart valves

Infections related to heart valve prosthesis are usually diagnosed with echocardiography, but it can miss key areas of infection. It is here that FDG PET or leukocute scintigraphy can step in, but a recent comparison study of the two nuclear medicine procedures published Nov. 13 in the Journal of Nuclear Medicine shows that FDG PET may be the best option.

Molecular imaging of stroke

While CT and MR are still the mainstays of detecting ischemic stroke, several SPECT and PET imaging techniques have been developed and are on the way to add comprehensive clinical information in the case of cerebrovascular disease. With this in mind, hybrid imaging such as PET/MR could provide a best-possible map of variables involved in stroke, according to a review published Oct. 9 in the Journal of Nuclear Medicine.

Flurpiridaz PET MPI data reveal lower dose than conventional SPECT

Myocardial perfusion imaging (MPI) with PET and F-18 flurpiridaz may reduce radiation dose while still providing comparable image quality to SPECT, the current standard, according to a study presented at the recent American Society of Nuclear Cardiology (ASNC) Annual Scientific Session held in Boston from Sept 18-21.

Measuring perfusion defects in SPECT MPI: A quantitative comparison

Three major quantitative softwares offer cardiologists a comprehensive map of myocardial perfusion and function, but they do not always agree, according to a study in the August issue of the Journal of Nuclear Cardiology.

Fatty meal prior to FDG PET/CT could improve coronary plaque imaging

A new protocol nuclear cardiologists could use to improve identification of coronary plaques involves decreasing F-18 FDG myocardial uptake to reveal more coronary detail in cardiac PET/CT. A high-fat meal prior to fasting seems to do the trick, according to a study published July 31 in the Journal of Nuclear Medicine.

Cardiac PET: Quantitating myocardial blood flow with F-18 flurpiridaz

The quantitative imaging of myocardial blood flow has been gaining momentum in recent years, as is the use of F-18 flurpiridaz, which has been shown to reveal a clear demarcation of disease in patients with CAD, according to a first-in-human quantitative imaging study published July 28 in the Journal of Nuclear Medicine.

PET imaging for myocardial innervation expands with F-18 labeled agent

First-in-human study of an investigational radiotracer, F-18 LMI1195, shows clear imaging of myocardial innervation via the norepinephrine transporter system—tipping off potential adverse cardiac events, according to a study published July 3 in the Journal of Nuclear Medicine.

Angiogenic gene therapy shows promise in phase III SPECT study

Taxus Cardium Pharmaceuticals Group have announced encouraging interim phase III cardiac SPECT imaging results from the international ASPIRE (Efficacy and Safety of Ad5FGF-4 for Myocardial Ischemia in Patients With Stable Angina Due to Coronary Artery Disease) trial. Generx Ad5FGF-4 is a potential angiogenic gene therapy for the development of new vascularization. The data was presented June 24 during the 2014 BIO International Convention in the company’s home base of San Diego.

Pages